Perioperative management of the bariatric surgery patient: focus on cardiac and anesthesia considerations.

Department of General Surgery, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
Cleveland Clinic Journal of Medicine (Impact Factor: 3.4). 04/2006; 73 Suppl 1:S51-6. DOI: 10.3949/ccjm.73.Suppl_1.S51
Source: PubMed

ABSTRACT Obesity is a major public health problem in developed nations worldwide. Currently, the only treatment for severe obesity (BMI > or = 35 kg/m2 with comorbidity) that provides long-term weight loss is bariatric surgery. Restrictive, malabsorptive, and combination procedures have been developed. Each type of procedure has its merits and unique set of risks and complications. Weight loss after bariatric surgery is accompanied by predictable improvement or resolution of obesity-related comorbidities and improved quality of life and life expectancy. Candidates for bariatric surgery are often at high risk for complications because of obesity-related comorbidities. Therefore, careful patient selection for bariatric surgery, together with well-designed strategies for preventing and managing complications, are keys to success. Close monitoring for nutritional deficiencies and short- and long-term complications is required to completely assess outcomes of these procedures.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUCTION: Being overweight is widespread in most societies and represents a major health threat. Gastric bypass surgery offers a highly effective mode of treatment for the morbidly obese patients. The procedures cause an alteration in normal gastrointestinal anatomy and physiology, with consequences not only on nutrient absorption, but also possibly on orally administered drugs. Bypass of the acidic environment of the stomach, partial impairment of bile salts-drug interactions and reduced absorptive surface, all create the potential for reduced absorption of drugs. AREAS COVERED: This article provides an overview of the effects of obesity and the most prevalent type of gastric bypass (Roux-en-Y) on pharmacokinetics. Articles for review were searched using Pubmed. EXPERT OPINION: The absorption of those drugs with known bioavailability issues generally seem to be most affected by bypass surgery. It is important to consider the effect of obesity on pharmacokinetics independent of the bypass procedure, because it leads to a dramatic drop in body mass over a relatively short period of time. This may be associated with reversals in the influence of obesity on drug disposition to characteristics more in line with leaner patients. Drugs will differ in their pharmacokinetic response to surgery, limiting any general conclusions regarding the impact of the surgery on drug disposition.
    Expert Opinion on Drug Metabolism &amp Toxicology 12/2012; · 2.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: As the prevalence of obesity sky rockets worldwide, the search for successful weight- management strategies follows. For select individuals, surgical intervention is the most appropriate weight-management intervention for sustained weight loss. Surgical procedures, such as the Roux-en-Y gastric bypass, sleeve gastrectomy, and laparoscopic adjustable gastric banding, bring about both dramatic weight loss and the ability to provide the patient with marked improvement in obesity-related conditions such as diabetes, arthritis, hypertension, and obstructive sleep apnea. In this article the authors will address the incidence of obesity and the criteria for weight-loss (bariatric) surgery; describe the preoperative evaluation and selection of the appropriate surgical procedure; discuss postoperative complications and required nursing care; and give readers a preview of future options for surgical weight loss.
    Online Journal of Issues in Nursing. 01/2009;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Laparoscopic adjustable gastric banding (LAGB) approved 6 years ago by the Federal Drug Administration is considered a safe and simple procedure for weight loss with a reported low mortality rate (0.05%) in the literature. The aim of the study was to probe the membership of the American Society for Bariatric Surgery (ASBS) to elucidate the incidence and possible causes of unreported operative and late mortality. A simple questionnaire on early (30 days) and late mortality after LAGB and reoperation for banding was sent to 1,437 of 2,500 members of ASBS. Incidences and causes were studied. Of the 1,437 questionnaires sent, 453 (31%) were returned. Sixty-eight of the surgeons did not do any LAGBs, 350 had no operative mortalities, and 35 (9%) reported at least one operative mortality and had a total of 36 operative deaths and 19 late deaths, for a grand total of 55. Five additional deaths occurred after reoperations for LAGB, following removal, revisions, or conversions to another bariatric procedure. Of 62 deaths, the causes were: 20 (33%) cardiac origin, 11 (18%) thromboembolic, ten (16%) GI perforations, three (5%) bleedings, and 18 miscellaneous. Of all deaths, 40% occurred remotely from the band insertion date. Although LAGB is technically simple, it carries a non-negligible short- and long-term mortality, with the majority being cardiac or thromboembolic. Late mortalities from LAGB and reoperations appear to be under-reported.
    Obesity Surgery 09/2009; 19(12):1657-63. · 3.10 Impact Factor

Full-text (2 Sources)

Available from
May 26, 2014